Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study

Chronic Hepatitis B Clinical Trial

— TeSLA  

Official title:

Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01804387
• Other study ID #: TeSLA study
• Status: Recruiting
• Phase: Phase 4
• First received: December 23, 2011
• Last updated: March 3, 2013
• Start date: May 2011
• Est. completion date: May 2014

Study information

• Verified date: March 2013
• Source: Korea University
• Contact: Hyung Joon Yim, M.D
• Phone: 82-31-412-5583
• Email: gudwns21[@]medimail.co.kr
• Is FDA regulated: No
• Health authority: Korea: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Lamivudine had been widely used for treatment-naïve chronic hepatitis B patients. However, development of antiviral resistance has been known as the major drawback: Incidence of lamivudine resistance was reported to be approximately 70% after 5 years (Lok AS et al, 2003). For the treatment of lamivudine resistance, adefovir has been widely used (Lok AS and McMahon B, 2009). However, switching to adefovir monotherapy was also reported to be at high risk of resistance, 25% at year 2 (Yeon JE et al, 2006). Recently, adding adefovir on lamivudine was shown to be superior to switching to adefovir monotherapy by decreasing the adefovir resistance (Rapti I et al, 2007, Lampertico P et al, 2007). However, combination of adefovir and lamivudine does not increase antiviral activity compared with adefovir monotherapy in patients with lamivudine resistance (Peters MG et al, 2004). As many patients are still viremic with the treatment of lamivudine and adefovir over 1 year, the investigators need more potent combination of the drugs. Telbivudine is a new nucleoside analogue with potent antiviral activity. The previous phase III study has shown the superiority of telbivudine over lamivudine in HBeAg positive and negative subjects (Lai CL et al, 2007). Therefore, telbivudine plus adefovir may be a better treatment option than lamivudine plus adefovir for the lamivudine-resistant chronic hepatitis B patients. No study assessing the efficacy of telbivudine plus adefovir has been conducted for these patients. The aim of this study is to evaluate the safety and efficacy of telbivudine plus adefovir compared with lamivudine plus adefovir in lamivudine resistant chronic hepatitis B patients at the end of 1 year follow-up,

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: May 2014
• Est. primary completion date: December 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. HBeAg positive or negative chronic hepatitis B patients (positive HBsAg more than 6 months)

2. Age = 18 years old, and =70 years old

3. Previous treatment with lamivudine more than 6 months

4. Being on lamivudine at the time of screening

5. Confirmed genotypic resistance to lamivudine by RFMP (rtM204V or I)

6. Presence of virologic breakthrough =1 log increase of HBV DNA above na dir)

7. HBV DNA = 20,000 IU/mL

8. Patient willing to give an informed consent (If patient is <20 years old, the parent or legal guardian also need to give an informed consent)

Exclusion Criteria:

1. Out of inclusion criteria

2. Presence of adefovir resistance (rtA181T or V, rtN236T) by RFMP assay

3. Laboratory abnormalities as follows at screening: AFP>100 ng/mL, serum phosphorous level<2.4 mg/dL, serum creatinine level> 1.5 mg/dL or creatinine clearance < 50 mL/min

4. Patient with a history of decompensated liver disease: Any patients with a history of ascites, hepatic encephalopathy, variceal bleeding, jaundice, or CTP>7 points should be excluded.

5. History of treatment with nucleos(t)ide analogues other than lamivudine more than 4 weeks

6. History of immune modulatory drugs (interferon, thymosin-alfa) within 24 weeks of screening

7. Liver transplant patient

8. Patient co-infected with HIV, HCV, or HDV

9. Patient with metabolic or genetic liver disease that may affect serum ALT level

10. Habitual alcohol consumption (>140 g/week for male, >70 g/week for female)

11. Patient not able to stop drugs that may affect ALT or HBV DNA level during study periods (ie. Steroid, immune-suppressants, non-steroidal anti-inflammatory drugs, acetaminophen,)

12. Pregnant or lactating woman

13. Menstruating woman unwilling to use appropriate methods of contraception (ie. Condom, oral contraceptives, tubal ligation)

14. Patient with hepatocellular carcinoma (treated or not treated)

15. Patient with any untreated malignancy

16. Patient with history of malignancy cured within 5 years of screening

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Hepatitis B
• Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis B, Chronic
• Hepatitis, Chronic

Intervention

Drug:
• telbivudine plus adefovir
telbivudine 600 mg qd plus adefovir 10 mg qd
• lamivudine plus adefovir
lamivudine 100 mg qd plus adefovir 10mg qd

Locations

Country	Name	City	State
Korea, Republic of	Korea University Ansan Hospital	Ansan	Gyeonggi-do

Sponsors (1)

Lead Sponsor	Collaborator
Korea University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Antiviral resistance rate		up to the end of year 1 (52 weeks)	Yes
Primary	The mean reduction of serum HBV DNA from the baseline at week 52.		up to the end of year 1 (52 weeks)	Yes
Secondary	HBV DNA undetectability(<20 IU/mL)	At the end of year 1 in the two groups, HBV DNA undetectability by real time PCR will be assessed.	up to the end of year 1 (52 weeks)	No
Secondary	mean serum HBV DNA level		up to the end of year 1 (52 weeks)	No
Secondary	rate of ALT normalization		up to the end of year 1 (52 weeks)	No
Secondary	rates of HBeAg loss		up to the end of year 1 (52 weeks)	No
Secondary	rate of HBeAg seroconversion at week 52.		up to the end of year 1 (52 weeks)	No